Clonidine extended-release tablets for the treatment of ADHD

Joan Daughton, Lindsey Corr, Howard Liu, Madeline West

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Treatment guidelines for ADHD recommend stimulants as a first-line therapy. However, as many as 15% of patients are unresponsive to these medications, while others are unable to tolerate stimulants. For some patients with ADHD, there is a clear need for nonstimulant therapies. This article aims to summarize the current evidence regarding the use of clonidine extended release (Kapvay™, Shionogi Pharma, GA, USA) in the treatment of children and adolescents with ADHD.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
Issue number2
StatePublished - Apr 2012

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health


Dive into the research topics of 'Clonidine extended-release tablets for the treatment of ADHD'. Together they form a unique fingerprint.

Cite this